Although various new agents targeting AR and testosterone synthetic pathways are under evaluation in clinical trials, more effective strategies will be necessary for preventing the transition to lethal states of prostate cancer, and this will require deeper understanding of underlying mechanisms of CRPC. Here, AR is linked to prostate cancer.